Tag: Zealand

Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ...

Company announcement – No. 19 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, May 12, 2022 – Zealand Pharma A/S (“Zealand”) ...

Company announcement – No. 16/ 2022 Zealand Pharma Amends Financing Agreement with Oberland Capital as Part of Company’s Refocused Strategy Amendment reduces the outstanding note principal balance from $100 million ...

New Strategic Partnership Expands Red Sift’s Global Reach; Delivers Powerful DMARC Managed Service to Help Protect More Enterprises From Email-Borne Threats LONDON--(BUSINESS WIRE)--Red Sift, provider of the only integrated cloud ...

Company announcement – No. 15 / 2022 Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10am ET) to Present First Quarter Results for 2022 Copenhagen, DK and ...

Company announcement – No. 13 / 2022 CORRECTION: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022 Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S ...

Company announcement – No. 13 / 2022 Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022 Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S ...

Company announcement – No. 9 / 2022 Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. Full Year Results ...

Company announcement – No. 5 / 2022 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022 Copenhagen, DK and Boston, MA, February 25, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ...

Company announcement – No. 4 / 2022 Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI) Top-line results expected in the second quarter ...